AlphaYouTNGX: Crystal Adam discloses securities transactions
By AlphaYouPublished Form 4
Crystal Adam
Reporting filer
Crystal Adam reported Exercise or conversion in Tango Therapeutics, Inc.: 27000 units of Common Stock, dated 2026-10-01. The full Form 4 contains 4 transaction entries.
- Disclosed
- Oct 5, 2026
Reported details
4 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Crystal Adam | 2026-10-01 | M | Exercise or conversion | 27000 | 5.2 | 142,743 | 4 days | Filed terms
|
| Common Stock | Crystal Adam | 2026-10-01 | S | Sale | 26400 | 24.4547 | 116,343 | 4 days | Filed terms
|
| Common Stock | Crystal Adam | 2026-10-01 | S | Sale | 600 | 25.32 | 115,743 | 4 days | Filed terms
|
| Stock Option (Right to Buy) (derivative) | Crystal Adam | 2026-10-01 | M | Exercise or conversion | 27000 | 0 | 233,040 | 4 days | Filed terms
|
Common Stock
- Owner
- Crystal Adam
- Date
- 2026-10-01
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 27000
- Price
- 5.2
- Following holdings
- 142,743
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-01
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- id: F1
- transaction Shares: 27000
- transaction Price Per Share: 5.2
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 142743
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Crystal Adam
- Date
- 2026-10-01
- Code
- S
- Action
- Sale
- Quantity
- 26400
- Price
- 24.4547
- Following holdings
- 116,343
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-01
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 26400
- transaction Price Per Share: 24.4547
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 116343
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Crystal Adam
- Date
- 2026-10-01
- Code
- S
- Action
- Sale
- Quantity
- 600
- Price
- 25.32
- Following holdings
- 115,743
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-01
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 600
- transaction Price Per Share: 25.32
- id: F3
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 115743
- direct Or Indirect Ownership: D
Stock Option (Right to Buy) (derivative)
- Owner
- Crystal Adam
- Date
- 2026-10-01
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 27000
- Price
- 0
- Following holdings
- 233,040
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Stock Option (Right to Buy)
- conversion Or Exercise Price: 5.2
- transaction Date: 2026-10-01
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- id: F1
- transaction Shares: 27000
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: D
- id: F4
- expiration Date: 2033-03-01
- underlying Security Title: Common Stock
- underlying Security Shares: 27000
- shares Owned Following Transaction: 233040
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Crystal Adam: President, R&D.
- The filing reports a Rule 10b5-1 trading plan.
- F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
- F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4: This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Original sources
Prepared automatically from public filing data. Report a correction.